StockData

NeoGenomics vs Veracyte

NEO and VCYT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NEO and VCYT compare

NeoGenomics and Veracyte are about the same size, with market caps of $2.0B and $1.9B.

Veracyte grew revenue faster over the last twelve months (17.3% versus 11.1% for NeoGenomics).

Veracyte keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −4.1% at NeoGenomics.

Veracyte scores higher on the StockData Score (16 against 11 for NeoGenomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNEOVCYT
Size and price
Market cap$2.0B$1.9B
Share price$15.41$24.01
Change, 1 year53.9%−39.8%
Change, 5 years−58.0%−42.2%
Beta (5Y)0.841.93
Employees2,500755
StockData Score
Total score1116 (better)
Valuation score34 (better)
Growth score4 (better)3
Performance score33
Health score16 (better)
Dividend score00
Valuation
P/E–17.1×
P/S2.5× (better)3.4×
P/B2.5×1.4× (better)
EV/EBITDA–12.9×
P/FCF–11.6×
FCF yield−1.4%8.6% (better)
Fair value$19.92$36.49
Margin of safety22.6%34.2% (better)
Growth
Revenue growth (TTM)11.1%17.3% (better)
Revenue growth, 5Y average10.4%34.5% (better)
Net income growth (TTM)–335%
EPS growth (TTM)–324%
Profitability
Gross margin44.8%71.7% (better)
Operating margin−6.3%18.8% (better)
Net margin−4.1%20.4% (better)
FCF margin−3.6%29.5% (better)
Return on equity−3.9%8.8% (better)
Return on invested capital−4.6%10.0% (better)
Financial health
Debt / equity0.47 (better)0.00
Interest coverage−15.2×–
Current ratio3.539.16 (better)
Altman Z-score2.3212.54 (better)
Piotroski F-score47 (better)
Dividends and buybacks
Buyback yield−0.02%–
Shareholder yield−0.02%0.00% (better)
Ownership
Held by institutions112%111%
Held by insiders1.5%1.7%
Insider net buying, 12 months−$717K (better)−$18.6M
Short interest, % of float10.3%12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.